Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $13.60.

Several research analysts have recently commented on OBIO shares. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Thursday, November 13th. Cowen began coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating for the company. Barclays decreased their target price on shares of Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. TD Cowen assumed coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Wednesday, October 8th.

Orchestra BioMed Price Performance

OBIO stock opened at $4.31 on Friday. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $6.16. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. The firm has a market capitalization of $243.39 million, a PE ratio of -2.37 and a beta of 0.63. The business has a 50 day simple moving average of $4.35 and a 200-day simple moving average of $3.39.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $0.74 million. Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%. Equities research analysts anticipate that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.

Institutional Trading of Orchestra BioMed

Several institutional investors and hedge funds have recently bought and sold shares of OBIO. Catalyst Funds Management Pty Ltd acquired a new position in Orchestra BioMed in the second quarter valued at about $31,000. Creative Planning purchased a new stake in shares of Orchestra BioMed in the 2nd quarter valued at approximately $40,000. XTX Topco Ltd purchased a new stake in shares of Orchestra BioMed in the 2nd quarter valued at approximately $45,000. Jane Street Group LLC acquired a new position in shares of Orchestra BioMed in the 2nd quarter worth approximately $50,000. Finally, Bank of America Corp DE boosted its position in shares of Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock worth $58,000 after purchasing an additional 5,678 shares during the period. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.